GGSK Read More GSK Says Immune Response from mRNA Flu Shot Surpasses Licensed CompetitorsSeptember 3, 2026 GSK plc (NYSE:GSK) plans to launch a Phase 3 clinical trial in September for its experimental mRNA seasonal…